The Federal Trade Commission’s (FTC) advertising disclosure rules for “material connections” are not new. The FTC has long required that advertising contain clear and conspicuous disclosures of endorsements and other material connections to ensure that consumers are not misled by hidden commercial relationships.[i] The longstanding expectation is simple: brands, influencers, and endorsers must make
On January 22, 2026, House Representatives Madeleine Dean (D-PA) and Nathaniel Moran (R-TX) introduced H.R. 7209, a bipartisan bill that could significantly reshape the relationship between copyright law and artificial intelligence. Known as the Transparency and Responsibility for Artificial Intelligence Networks (TRAIN) Act, the proposal seeks to give copyright owners a clearer path to
When discussing the litigation challenges deepfake technology poses, one typically thinks of difficulties protecting individual privacy rights, complications prosecuting anonymous actors, the lack of law regulating deepfake usage outside commercial context, and authentication and evidentiary issues. Less prevalent is a discussion of potential liability companies face for fraud perpetrated on their customers. Yet, the proliferation of
On January 12, the CFPB and DOJ withdrew their October 2023 joint statement addressing how creditors’ consideration of immigration or citizenship status may intersect with the ECOA. The joint statement, published in the Federal Register on October 18, 2023, had cautioned that certain creditor policies affecting noncitizen borrowers could, in some circumstances, raise fair lending concerns.
I have to admit to an instinctive gut reaction of skepticism when Kimberly Powell of NVIDIA on Monday said that “AI is a once-in-a-lifetime shift for the healthcare industry.” Intellectually, I am excited by AI and its possibilities, but I well know healthcare’s slow and steady approach and rigid workflows can chew up technology gains
Last week, the U.S. Food and Drug Administration (“FDA”) rung in the new year with a flurry of device-related activity, updating two final guidance documents and withdrawing a guidance published back in 2017. The two final guidance documents released on January 6, 2026 pertain to (1) General Wellness Devices and (2) Clinical Decision Support Software,
J.P. Morgan continues to surprise us at lunch, with the Mayor of San Francisco sharing on Monday an update on recent improvements in the city. Then on Tuesday at the Grand Ballroom lunch, it was the first episode of my favorite new sit-com “Everyone but Abe…”
At the 44th Annual J.P. Morgan Healthcare Conference, Jamie Dimon (CEO of J.P. Morgan) told the audience that we should be teaching healthcare in school from kindergarten to 12th grade. He was right…but we don’t. And, therefore, artificial intelligence will come to dominate the U.S. healthcare system, which spent over $5.6 trillion in 2025. Wait, you might say,
On December 11, 2025, President Trump signed an Executive Order titled Ensuring a National Policy Framework for Artificial Intelligence (the “EO”). This EO targets state laws addressing artificial intelligence and creates potential compliance issues employers must carefully navigate.
Just in time for the holidays, on December 15, 2025, the U.S. Food and Drug Administration (“FDA”) Office of Prescription Drug Promotion (“OPDP”) issued an untitled letter (the “Letter”) to Karuna Therapeutics, Inc., a Bristol Myers Squibb Company, concerning a direct-to-consumer broadcast ad for Cobenfy™ (xanomeline and trospium chloride), a drug approved for the treatment